Published in Biometrics on September 01, 2004
Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med (2011) 3.83
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
Modelling the cumulative risk of a false-positive screening test. Stat Methods Med Res (2010) 1.87
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst (2013) 1.81
A semiparametric censoring bias model for estimating the cumulative risk of a false-positive screening test under dependent censoring. Biometrics (2013) 1.52
Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst (2009) 1.24
Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme. J Epidemiol Community Health (2006) 1.23
Statistical Methods for Estimating the Cumulative Risk of Screening Mammography Outcomes. Cancer Epidemiol Biomarkers Prev (2015) 0.79
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med (2013) 2.66
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst (2011) 2.31
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27
Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst (2005) 2.24
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2009) 2.20
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52
The word "cancer": how language can corrupt thought. BMJ (2013) 1.51
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
A population approach to precision medicine. Am J Prev Med (2012) 1.44
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
Lung cancer: interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. Radiology (2007) 1.32
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst (2010) 1.29
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol (2002) 1.27
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer (2009) 1.22
Biomarkers, subgroup evaluation, and clinical trial design. Discov Med (2012) 1.21
Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointest Endosc (2012) 1.18
National Children's Study: update in 2010. Mt Sinai J Med (2011) 1.17
Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer (2009) 1.15
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. Biostatistics (2005) 1.15
Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med (2012) 1.14
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
CT quality assurance in the lung screening study component of the National Lung Screening Trial: implications for multicenter imaging trials. AJR Am J Roentgenol (2009) 1.12
The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? BMC Med Res Methodol (2004) 1.11
Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer (2007) 1.10
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer (2005) 1.08
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis. Stat Methods Med Res (2005) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Cancer screening in theory and in practice. J Clin Oncol (2005) 1.06
Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study. J Thorac Oncol (2009) 1.03
The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. Urol Oncol (2004) 1.03
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2006) 1.01
Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials (2010) 1.01
Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes. BMC Med Res Methodol (2003) 0.99
Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol (2006) 0.99
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst (2013) 0.98
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med Res Methodol (2003) 0.98
Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int (2010) 0.97
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. Gynecol Oncol (2011) 0.93
Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet Gynecol (2013) 0.92
Adherence to repeat screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer (2002) 0.91
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen (2011) 0.89
Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected. Stat Med (2009) 0.88